Extended-release metformin causes fewer stomach side effects than the standard form.
14 sources: 9 positive, 3 partly, 2 negative.
Researchers say
No researcher counted yet.
Studies show
9 positive, 3 partly, 2 negative
14 papers we read
-
Other primary study, Diabetol Metab Syndr, 2010, PMID 20298568
Positive Study
Read the paper on PubMed →Conclusions Switchover to metformin XR resulted in a significant improvement in gastrointestinal tolerability with marked reductions in diarrhoea and nausea.
-
Other primary study, J Diabetes, 2012, PMID 22742083
Positive Study
Read the paper on PubMed →In particular, we confirm in a short-term study that in Asian, as well as Caucasian, populations, MXR taken once-daily has improved GI tolerability compared with MIR and other OADs taken over the long term, resulting in fewer GI side-effects and treatment discontinuations.
-
Controlled trial, Drug Des Devel Ther, 2017, PMID 28553078
Positive Study
Read the paper on PubMed →Adverse events Adverse events were more common with metformin IR formulation, both after 3 months ( P <0.05 vs metformin XR) and after 6 months ( P <0.01 vs metformin XR) ( Figures 3 and 4 ).
-
Other primary study, BMJ Open, 2018, PMID 30037872
Positive Study
Read the paper on PubMed →After multivariable adjustment, side effects were less common in men and in those initially prescribed ER metformin, and were more common in patients receiving starting dose of metformin >1500 mg per day ( table 3 ).
-
Controlled trial, Front Endocrinol (Lausanne), 2021, PMID 34659110
Positive Study
Read the paper on PubMed →We found that both forms of metformin had comparable efficacy in this treatment, but the SR tablets had significantly lower ADRs, primarily the gastrointestinal adverse reactions, than the original metformin form.
-
Pooled analysis, Front Endocrinol (Lausanne), 2022, PMID 36187122
Positive Study
Read the paper on PubMed →Metformin immediate-release is associated with a higher risk of diarrhea and bloating compared to metformin extended release.
-
Other primary study, Endocr Metab Immune Disord Drug Targets, 2024, PMID 38425116
Positive Study
Read the paper on PubMed →In the overall study population, the frequency of patients experiencing diarrhea or abdominal pain after 8 weeks of treatment with metformin-ER was reduced by 88% and 86%, respectively, compared to the pre-switch period.
-
Pooled analysis, BMC Endocr Disord, 2024, PMID 39350158
Positive Study
Read the paper on PubMed →The use of metformin XR formulation is associated with lower risk of GI AE compared to IR formulation.
-
Trial or observed group, Medicine (Baltimore), 2026, PMID 41559978
Positive Study
Read the paper on PubMed →Notably, only 24.5% of XR patients experienced any GI side effect, compared to 45.2% of IR patients ( P <.05).
-
Trial or observed group, Curr Med Res Opin, 2004, PMID 15119994
Partly Study
Read the paper on PubMed →Despite this, the frequency of any GI AE was similar between metformin-XR and immediate release metformin (11.94 vs. 11.39%, p = 0.86).
-
Controlled trial, Diabetes Obes Metab, 2018, PMID 28857388
Partly Study
Read the paper on PubMed →In this study, down‐titration because of metformin intolerance 1 was necessary in almost 3 times as many patients treated with metformin IR compared with metformin XR.
-
Other primary study, Diabetes Ther, 2021, PMID 34075573
Partly Study
Read the paper on PubMed →There was a non-statistically significant reduction in the likelihood of experiencing GI side effects between individuals randomised to met-XR versus met-IR (OR 0.69, 95% CI 0.45–1.07, I 2 = 71%, p = 0.10), based on nine studies including 2164 participants (Fig. 5 a).
-
Other primary study, Pediatr Diabetes, 2021, PMID 33179823
Negative Study
Read the paper on PubMed →The prevalence of GI symptoms was similar in youth treated with metformin SR and XR - a finding that, to our knowledge, has not been previously reported.
-
Other primary study, Front Pharmacol, 2021, PMID 34079464
Negative Study
Read the paper on PubMed →There was very low– to moderate-level evidence for a lack of difference between metformin XR and IR in adverse events of abdominal pain (RR, 1.15, 95% CI 0.57–2.33), all-cause death (RR, 3.02, 95% CI 0.12–73.85), any adverse events (RR, 1.14, 95% CI 0.97-1.34), any adverse events leading to discontinuation (RR, 1.51, 95% CI 0.82–2.8), any gastrointestinal adverse events (RR, 1.09, 95% CI 0.93–1.29), diarrhea (RR, 0.82, 95% CI 0.53–1.27), flatulence (RR, 0.43, 95% CI 0.15–1.23), nausea (RR, 0.97, 95% CI 0.64–1.47), severe adverse events (RR, 0.64, 95% CI 0.28–1.42), and vomiting (RR, 1.46, 95% CI 0.6–3.56).
5 more not counted · see why
The study is not yet read in full. 5
- Controlled trial, Diabetes Care, 2006, PMID 16567811
- Controlled trial, Zhonghua Yi Xue Za Zhi, 2007, PMID 17686255
- Controlled trial, J Ayub Med Coll Abbottabad, 2017, PMID 28718236
- Controlled trial, Diabetes Obes Metab, 2018, PMID 29227571
- Pooled analysis, Diabetes Res Clin Pract, 2021, PMID 33887354
Show the receipts from 14 sources
-
Other primary study, Diabetol Metab Syndr, 2010, PMID 20298568 Study · positive
Conclusions Switchover to metformin XR resulted in a significant improvement in gastrointestinal tolerability with marked reductions in diarrhoea and nausea.
-
Other primary study, J Diabetes, 2012, PMID 22742083 Study · positive
In particular, we confirm in a short-term study that in Asian, as well as Caucasian, populations, MXR taken once-daily has improved GI tolerability compared with MIR and other OADs taken over the long term, resulting in fewer GI side-effects and treatment discontinuations.
-
Controlled trial, Drug Des Devel Ther, 2017, PMID 28553078 Study · positive
Adverse events Adverse events were more common with metformin IR formulation, both after 3 months ( P <0.05 vs metformin XR) and after 6 months ( P <0.01 vs metformin XR) ( Figures 3 and 4 ).
-
Other primary study, BMJ Open, 2018, PMID 30037872 Study · positive
After multivariable adjustment, side effects were less common in men and in those initially prescribed ER metformin, and were more common in patients receiving starting dose of metformin >1500 mg per day ( table 3 ).
-
Controlled trial, Front Endocrinol (Lausanne), 2021, PMID 34659110 Study · positive
We found that both forms of metformin had comparable efficacy in this treatment, but the SR tablets had significantly lower ADRs, primarily the gastrointestinal adverse reactions, than the original metformin form.
-
Pooled analysis, Front Endocrinol (Lausanne), 2022, PMID 36187122 Study · positive
Metformin immediate-release is associated with a higher risk of diarrhea and bloating compared to metformin extended release.
-
Other primary study, Endocr Metab Immune Disord Drug Targets, 2024, PMID 38425116 Study · positive
In the overall study population, the frequency of patients experiencing diarrhea or abdominal pain after 8 weeks of treatment with metformin-ER was reduced by 88% and 86%, respectively, compared to the pre-switch period.
-
Pooled analysis, BMC Endocr Disord, 2024, PMID 39350158 Study · positive
The use of metformin XR formulation is associated with lower risk of GI AE compared to IR formulation.
-
Trial or observed group, Medicine (Baltimore), 2026, PMID 41559978 Study · positive
Notably, only 24.5% of XR patients experienced any GI side effect, compared to 45.2% of IR patients ( P <.05).
-
Trial or observed group, Curr Med Res Opin, 2004, PMID 15119994 Study · partly
Despite this, the frequency of any GI AE was similar between metformin-XR and immediate release metformin (11.94 vs. 11.39%, p = 0.86).
-
Controlled trial, Diabetes Obes Metab, 2018, PMID 28857388 Study · partly
In this study, down‐titration because of metformin intolerance 1 was necessary in almost 3 times as many patients treated with metformin IR compared with metformin XR.
-
Other primary study, Diabetes Ther, 2021, PMID 34075573 Study · partly
There was a non-statistically significant reduction in the likelihood of experiencing GI side effects between individuals randomised to met-XR versus met-IR (OR 0.69, 95% CI 0.45–1.07, I 2 = 71%, p = 0.10), based on nine studies including 2164 participants (Fig. 5 a).
-
Other primary study, Pediatr Diabetes, 2021, PMID 33179823 Study · negative
The prevalence of GI symptoms was similar in youth treated with metformin SR and XR - a finding that, to our knowledge, has not been previously reported.
-
Other primary study, Front Pharmacol, 2021, PMID 34079464 Study · negative
There was very low– to moderate-level evidence for a lack of difference between metformin XR and IR in adverse events of abdominal pain (RR, 1.15, 95% CI 0.57–2.33), all-cause death (RR, 3.02, 95% CI 0.12–73.85), any adverse events (RR, 1.14, 95% CI 0.97-1.34), any adverse events leading to discontinuation (RR, 1.51, 95% CI 0.82–2.8), any gastrointestinal adverse events (RR, 1.09, 95% CI 0.93–1.29), diarrhea (RR, 0.82, 95% CI 0.53–1.27), flatulence (RR, 0.43, 95% CI 0.15–1.23), nausea (RR, 0.97, 95% CI 0.64–1.47), severe adverse events (RR, 0.64, 95% CI 0.28–1.42), and vomiting (RR, 1.46, 95% CI 0.6–3.56).